Table 3.

List of clinical trials in gastric cancer using immune checkpoint inhibitors.

Reference	Title	Sponsor and collaborations	Inhibitor target	Drug	Phase	Status	Duration
NCT02494583	Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin + 5-Fluorouracil Versus Placebo + Cisplatin + 5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric Gastroesophageal Junction (GEJ)	Merck Sharp & Dohme Corp.	PD-1	Pembrolizumab	3	Recruiting	Study first received: June 8, 2015 Estimated completion date: April, 2019
NCT02335411	A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in combination with Cisplatin + 5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059)	Merck Sharp & Dohme Corp.	PD-1	Pembrolizumab	2	Recruiting	Study first received: February, 2015 Last updated: July 16, 2015
NCT02340975	A Phase 1b/2 Study of MEDI4736 with Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma	MedImmune LLC	PD-L1 CTLA-4	MEDI4736 (Anti-PD-L1) Tremelimumab (Anti CTLA-4)	1 & 2	Recruiting	Study first received: January 14, 2015 Last updated: May 15, 2015
NCT01975831	A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Solid Tumors	Ludwig Institute for Cancer Research	PD-L1 CTLA-4	MEDI4736 (Anti-PD-L1) Tremelimumab (Anti CTLA-4)	1	Not yet recruiting	Study first received: December, 2013 Estimated completion date: December, 2016
NCT01585987	A Randomized, Open-Label, Two-Arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab versus Best Supportive Care Following First-Line Chemotherapy in Subjects with Unresectable Locally Advanced/Metastatic Gastric or Gastro-Esophageal Junction Cancer	Bristol-Myers Squibb	CTLA-4	Ipilimumab	2	Completed	Study first received: April 25, 2012 Completed: April, 2015